What are Scynexis Inc's Business Segments?
Scynexis Inc is a pharmaceutical company that specializes in the discovery, development, and commercialization of anti-infectives. The company has a diverse product portfolio which includes various segments, products, and services.
Segments: 1. Clinical Development: Scynexis has a robust clinical development program in place focusing on the development of novel anti-infective therapies. The company is focused on developing therapies for various infectious diseases, including fungal infections and viral infections. 2. Commercialization: Scynexis has a strong focus on commercializing its anti-infective therapies in the United States and international markets. The company has a dedicated sales and marketing team that works closely with healthcare providers and hospitals to promote its products.
Products and Services: 1. Ibrexafungerp: This is Scynexis' lead product candidate which is a novel oral antifungal therapy for the treatment of various fungal infections, including Candida and Aspergillus. Ibrexafungerp is currently in the late stages of clinical development and has been granted Qualified Infectious Disease Product (QIDP) designation by the FDA for the treatment of invasive candidiasis and invasive aspergillosis. 2. SCY-078: SCY-078 is an experimental antifungal therapy that is currently in clinical development. The drug is being studied for the treatment of various fungal infections, including Candida and Aspergillus. 3. Contract Research: Scynexis offers contract research services to pharmaceutical companies and biotechnology firms. The company's contract research services include drug discovery, preclinical testing, and clinical development services. 4. Research Collaborations: Scynexis has entered into various research collaborations with academic institutions and other pharmaceutical companies to advance the development of new anti-infective therapies.
In summary, Scynexis Inc offers a wide range of products and services focused on the research, development, and commercialization of novel anti-infective therapies. The company is committed to advancing the treatment of various infectious diseases and has a diversified product portfolio that includes both clinical-stage and preclinical-stage products.
|